88
Views
30
CrossRef citations to date
0
Altmetric
Article

Brk/Protein Tyrosine Kinase 6 Phosphorylates p27KIP1, Regulating the Activity of Cyclin D–Cyclin-Dependent Kinase 4

, , , , , , , & show all
Pages 1506-1522 | Received 30 Sep 2014, Accepted 17 Jan 2015, Published online: 20 Mar 2023

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Katia Coulonval, Vincent Vercruysse, Sabine Paternot, Jaime M. Pita, Robert Corman, Eric Raspé & Pierre P. Roger. (2022) Monoclonal antibodies to activated CDK4: use to investigate normal and cancerous cell cycle regulation and involvement of phosphorylations of p21 and p27. Cell Cycle 21:1, pages 12-32.
Read now

Articles from other publishers (28)

Jamie O. Brett, Paige E. Herman, Erica L. Mayer, Aditya Bardia & Seth A. Wander. (2022) Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Receptor-Positive (HR +) Breast Cancer: Spotlight on Convergent CDK6 Upregulation and Immune Signaling. Current Breast Cancer Reports 14:4, pages 222-232.
Crossref
Hsuan-Hsiang Peng, Hao-Chin Yang, Darius Rupa, Chun-Han Yen, Ya-Wen Chiu, Wei-Jia Yang, Fuh-Jinn Luo & Ta-Chun Yuan. (2022) ACK1 upregulated the proliferation of head and neck squamous cell carcinoma cells by promoting p27 phosphorylation and degradation. Journal of Cell Communication and Signaling 16:4, pages 567-578.
Crossref
Emily K. Moore, Marianne Strazza & Adam Mor. (2022) Combination Approaches to Target PD-1 Signaling in Cancer. Frontiers in Immunology 13.
Crossref
Heidelinde Jäkel, Martin Taschler, Karin Jung, Christina Weinl, Fragka Pegka, Michael Keith Kullmann, Silvio Roland Podmirseg, Sayantanee Dutta, Markus Moser & Ludger Hengst. (2022) Inability to phosphorylate Y88 of p27Kip1 enforces reduced p27 protein levels and accelerates leukemia progression. Leukemia 36:7, pages 1916-1925.
Crossref
Jacob B. Swadling, Tobias Warnecke, Kyle L. Morris & Alexis R. Barr. (2022) Conserved Cdk inhibitors show unique structural responses to tyrosine phosphorylation. Biophysical Journal 121:12, pages 2312-2329.
Crossref
Gian Luca Rampioni Vinciguerra, Maura Sonego, Ilenia Segatto, Alessandra Dall’Acqua, Andrea Vecchione, Gustavo Baldassarre & Barbara Belletti. (2022) CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review. Frontiers in Oncology 12.
Crossref
Anne Fassl, Yan GengPiotr Sicinski. (2022) CDK4 and CDK6 kinases: From basic science to cancer therapy. Science 375:6577.
Crossref
Irina Jilishitz, Jason Luis Quiñones, Priyank Patel, Grace Chen, Jared Pasetsky, Allison VanInwegen, Scott Schoninger, Manasi P. Jogalekar, Vladislav Tsiperson, Lingyue Yan, Yun Wu, Susan R.S. Gottesman, Jonathan Somma & Stacy W. Blain. (2021) NP-ALT, a Liposomal:Peptide Drug, Blocks p27Kip1 Phosphorylation to Induce Oxidative Stress, Necroptosis, and Regression in Therapy-Resistant Breast Cancer Cells. Molecular Cancer Research 19:11, pages 1929-1945.
Crossref
Gian Luca Rampioni Vinciguerra, Alessandra Dall’Acqua, Ilenia Segatto, Maria Chiara Mattevi, Francesca Russo, Andrea Favero, Roberto Cirombella, Giorgia Mungo, Davide Viotto, Javad Karimbayli, Margherita Pesce, Andrea Vecchione, Barbara Belletti & Gustavo Baldassarre. (2021) p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer. Cell Death & Disease 12:10.
Crossref
Bin Wang, Rui Li, Shuai Wu, Xin Liu, Jianlin Ren, Jing Li, Kaixin Bi, Yanhong Wang & Hongyan Jia. (2021) Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms. Frontiers in Oncology 11.
Crossref
Georgia Gomatou, Ioannis Trontzas, Stephanie Ioannou, Maria Drizou, Nikolaos Syrigos & Elias Kotteas. (2021) Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors. Molecular Biology Reports 48:1, pages 915-925.
Crossref
Samuel Hume, Grigory L Dianov & Kristijan Ramadan. (2020) A unified model for the G1/S cell cycle transition. Nucleic Acids Research 48:22, pages 12483-12501.
Crossref
Milica B. Gilic & Angela L. Tyner. (2020) Targeting protein tyrosine kinase 6 in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1874:2, pages 188432.
Crossref
Eleanor Wendy Trotter & Iain Michael Hagan. (2020) Release from cell cycle arrest with Cdk4/6 inhibitors generates highly synchronized cell cycle progression in human cell culture. Open Biology 10:10.
Crossref
Stephen M. Smith. (2020) Molecular biology meets the endocrine pathologist: an appraisal of p27 in thyroid malignancy. Diagnostic Histopathology 26:5, pages 216-223.
Crossref
Scott F. Schoninger & Stacy W. Blain. (2020) The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer. Molecular Cancer Therapeutics 19:1, pages 3-12.
Crossref
Charles J. Sherr. (2019) Surprising regulation of cell cycle entry. Science 366:6471, pages 1315-1316.
Crossref
Keelan Z. Guiley, Jack W. Stevenson, Kevin Lou, Krister J. BarkovichVishnu KumarasamyTilini U. Wijeratne, Katharine L. Bunch, Sarvind Tripathi, Erik S. KnudsenAgnieszka K. WitkiewiczKevan M. Shokat & Seth M. Rubin. (2019) p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition. Science 366:6471.
Crossref
Noelia V. Miret, Carolina A. Pontillo, Lorena V. Zárate, Diana Kleiman de Pisarev, Claudia Cocca & Andrea S. Randi. (2019) Impact of endocrine disruptor hexachlorobenzene on the mammary gland and breast cancer: The story thus far. Environmental Research 173, pages 330-341.
Crossref
Susan R.S. Gottesman, Jonathan Somma, Vladislav Tsiperson, Lisa Dresner, Usha Govindarajulu, Priyank Patel & Stacy W. Blain. (2019) Tyrosine Phosphorylation of p27Kip1 Correlates with Palbociclib Responsiveness in Breast Cancer Tumor Cells Grown in Explant Culture. Molecular Cancer Research 17:3, pages 669-675.
Crossref
Qilian He, Xingmei Nan, Silin Li, Shanshan Su, Ke Ma, Zhanqiang Li, Dianxiang Lu & Rili Ge. (2018) Tsantan Sumtang Alleviates Chronic Hypoxia-Induced Pulmonary Hypertension by Inhibiting Proliferation of Pulmonary Vascular Cells. BioMed Research International 2018, pages 1-13.
Crossref
Cristina Guarducci, Martina Bonechi, Matteo Benelli, Chiara Biagioni, Giulia Boccalini, Dario Romagnoli, Roberto Verardo, Rachel Schiff, C. Kent Osborne, Carmine De Angelis, Angelo Di Leo, Luca Malorni & Ilenia Migliaccio. (2018) Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. npj Breast Cancer 4:1.
Crossref
Oriol Bachs, Edurne Gallastegui, Serena Orlando, Anna Bigas, José Manuel Morante-Redolat, Joan Serratosa, Isabel Fariñas, Rosa Aligué & Maria Jesús Pujol. (2018) Role of p27Kip1 as a transcriptional regulator. Oncotarget 9:40, pages 26259-26278.
Crossref
Priyank Patel, Vladislav Tsiperson, Susan R.S. Gottesman, Jonathan Somma & Stacy W. Blain. (2018) Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells. Molecular Cancer Research 16:3, pages 361-377.
Crossref
Matthew InghamGary K. Schwartz. (2017) Cell-Cycle Therapeutics Come of Age. Journal of Clinical Oncology 35:25, pages 2949-2959.
Crossref
Cristina Guarducci, Martina Bonechi, Giulia Boccalini, Matteo Benelli, Emanuela Risi, Angelo Di Leo, Luca Malorni & Ilenia Migliaccio. (2017) Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response. Breast Care 12:5, pages 304-308.
Crossref
Alessandro Del Gobbo & Stefano Ferrero. (2017) Immunohistochemical Markers as Predictors of Histopathologic Response and Prognosis in Rectal Cancer Treated with Preoperative Adjuvant Therapy: State of the Art. Gastroenterology Research and Practice 2017, pages 1-6.
Crossref
Raghuveera Kumar Goel & Kiven Erique Lukong. (2015) Tracing the footprints of the breast cancer oncogene BRK — Past till present. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1856:1, pages 39-54.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.